摘要
目的观察预先静脉给予硫酸镁对伊布利特转复心房颤动/心房扑动的影响。方法选择符合条件的心房颤动/心房扑动患者64例,随机单盲法分为安慰剂+伊布利特组(对照组)和硫酸镁+伊布利特组(试验组),分别在1 h内静脉滴注氯化钠注射液100 mL或氯化钠注射液100 mL加25%硫酸镁20 mL,10 min后给予伊布利特静脉注射,观察两组患者的心房颤动/心房扑动转复率及不良事件发生情况。结果对照组与试验组对于心房颤动/心房扑动的转复率分别为50%及84%,两组比较差异显著(P<0.05);两组间不良反应发生率无显著差异(P>0.05)。结论预先静脉给予硫酸镁可显著提高伊布利特转复心房颤动/心房扑动的成功率。
AIM To investigate the influence of pre-injected magnesium sullate on me conversion ellcct of ibutilide on atrial fibrillation or flutter. METHODS Sixty-four patients who has atrial fibrillation or flutter were randomized tO give placebo plus ibutilide group （control group） or magnesium sulfate plus ibutilide group （trial group） , receive either an infusion of 100 mL of 0.9% sodium chloride or the same amount of sodium chloride with 20 mL of 25% magnesium sulfate in one hour. After 10 rain, ibutilide was infused. The conversion rate of atrial fibrillation or flutter and adverse events were observed. RESULTS Conversion rate of ibutilide for atrial fibrillation or flutter in the control group and the trial group is 50% and 84% respectively （P 〈 0.05）. Adverse events are not significantly different between the two groups. CONCLUSION Preinjection of magnesium sulfate enhances the ability of ibutilide for the conversion of atrial fibrillation or flutter.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2013年第3期208-211,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
伊布利特
硫酸镁
心房颤动
心房扑动
转复率
ibutilide
magnesium sulfate
atrial fibrillation
atrial flutter
conversion rate
